机构：[1]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.临床科室血液内科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.医技科室病理科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[3]Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.首都医科大学附属北京同仁医院首都医科大学附属同仁医院
This work was supported by National Natural Science
Foundation of China (No. 82170181), Beijing Hospitals
Authority Youth Programme (No. QML20200201),
Beijing Natural Science Foundation (No. 7222027), and
CSH Young Scholars and 3SBioPharmaceutical joint
research project (No. KYC2201001).
第一作者机构：[1]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
通讯作者：
通讯机构：[1]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.[3]Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.[*1]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
推荐引用方式(GB/T 7714)：
Fu Ruiying,Liang Yuanzheng,Wei Liqiang,et al.Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma[J].CHINESE MEDICAL JOURNAL.2023,136(6):732-734.doi:10.1097/CM9.0000000000002570.
APA：
Fu Ruiying,Liang Yuanzheng,Wei Liqiang,Liu Xindi,Piao Yingshi&Wang Liang.(2023).Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma.CHINESE MEDICAL JOURNAL,136,(6)
MLA：
Fu Ruiying,et al."Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma".CHINESE MEDICAL JOURNAL 136..6(2023):732-734
